AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis
USA - NASDAQ:AMPH - US03209R1032 - Common Stock
24.52 USD
-0.2 (-0.81%)
24.52 USD
0 (0%)
Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 192 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
AMPH had a positive operating cash flow in the past year.
AMPH had positive earnings in each of the past 5 years.
AMPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 8.34%, AMPH belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
AMPH has a Return On Equity of 17.78%. This is amongst the best in the industry. AMPH outperforms 91.15% of its industry peers.
Looking at the Return On Invested Capital, with a value of 10.47%, AMPH belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is below the industry average of 15.45%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.34% | ||
| ROE | 17.78% | ||
| ROIC | 10.47% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
With an excellent Profit Margin value of 18.64%, AMPH belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
AMPH's Profit Margin has improved in the last couple of years.
AMPH has a better Operating Margin (25.14%) than 91.15% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
AMPH has a Gross Margin of 49.86%. This is in the better half of the industry: AMPH outperforms 64.06% of its industry peers.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.14% | ||
| PM (TTM) | 18.64% | ||
| GM | 49.86% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
Compared to 1 year ago, AMPH has less shares outstanding
AMPH has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMPH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.46 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.46, AMPH is in the better half of the industry, outperforming 67.71% of the companies in the same industry.
The Debt to FCF ratio of AMPH is 5.54, which is a neutral value as it means it would take AMPH, 5.54 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AMPH (5.54) is better than 81.25% of its industry peers.
A Debt/Equity ratio of 0.80 indicates that AMPH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.80, AMPH is not doing good in the industry: 70.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.54 | ||
| Altman-Z | 2.46 |
ROIC/WACC1.25
WACC8.36%
2.3 Liquidity
A Current Ratio of 3.29 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio (3.29) which is in line with its industry peers.
A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
AMPH's Quick ratio of 2.21 is in line compared to the rest of the industry. AMPH outperforms 46.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased strongly by -13.47% in the last year.
AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
AMPH shows a small growth in Revenue. In the last year, the Revenue has grown by 1.37%.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%
3.2 Future
The Earnings Per Share is expected to grow by 0.50% on average over the next years.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.23% yearly.
EPS Next Y-11.58%
EPS Next 2Y-0.74%
EPS Next 3Y2.34%
EPS Next 5Y0.5%
Revenue Next Year-1.16%
Revenue Next 2Y2.72%
Revenue Next 3Y3.26%
Revenue Next 5Y4.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.07, the valuation of AMPH can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.79% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.91, AMPH is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.45, the valuation of AMPH can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.27% of the companies listed in the same industry.
AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.07 | ||
| Fwd PE | 6.45 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 94.79% of the companies are valued more expensively.
91.15% of the companies in the same industry are more expensive than AMPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.37 | ||
| EV/EBITDA | 6.27 |
4.3 Compensation for Growth
The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.11
EPS Next 2Y-0.74%
EPS Next 3Y2.34%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.52
-0.2 (-0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners71.91%
Inst Owner Change-0.69%
Ins Owners9.28%
Ins Owner Change3.46%
Market Cap1.14B
Revenue(TTM)722.68M
Net Income(TTM)134.71M
Analysts78.33
Price Target33.86 (38.09%)
Short Float %11.26%
Short Ratio9.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.06%
Min EPS beat(2)5.65%
Max EPS beat(2)12.46%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-4.74%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)11.25%
EPS beat(12)8
Avg EPS beat(12)16.86%
EPS beat(16)12
Avg EPS beat(16)21.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-1.36%
Revenue beat(4)0
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)-1.36%
Revenue beat(8)2
Avg Revenue beat(8)-1.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)9
Avg Revenue beat(16)0.92%
PT rev (1m)0%
PT rev (3m)1.37%
EPS NQ rev (1m)0.06%
EPS NQ rev (3m)4.01%
EPS NY rev (1m)-0.61%
EPS NY rev (3m)6.42%
Revenue NQ rev (1m)-0.94%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.07 | ||
| Fwd PE | 6.45 | ||
| P/S | 1.58 | ||
| P/FCF | 10.37 | ||
| P/OCF | 7.14 | ||
| P/B | 1.51 | ||
| P/tB | 6.37 | ||
| EV/EBITDA | 6.27 |
EPS(TTM)3.47
EY14.15%
EPS(NY)3.8
Fwd EY15.51%
FCF(TTM)2.36
FCFY9.64%
OCF(TTM)3.43
OCFY14%
SpS15.54
BVpS16.29
TBVpS3.85
PEG (NY)N/A
PEG (5Y)0.11
Graham Number35.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.34% | ||
| ROE | 17.78% | ||
| ROCE | 12.63% | ||
| ROIC | 10.47% | ||
| ROICexc | 12.47% | ||
| ROICexgc | 23.95% | ||
| OM | 25.14% | ||
| PM (TTM) | 18.64% | ||
| GM | 49.86% | ||
| FCFM | 15.21% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.54 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 93.66% | ||
| Cap/Sales | 6.88% | ||
| Interest Coverage | 7.38 | ||
| Cash Conversion | 68.01% | ||
| Profit Quality | 81.61% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.46 |
F-Score5
WACC8.36%
ROIC/WACC1.25
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
EPS Next Y-11.58%
EPS Next 2Y-0.74%
EPS Next 3Y2.34%
EPS Next 5Y0.5%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%
Revenue Next Year-1.16%
Revenue Next 2Y2.72%
Revenue Next 3Y3.26%
Revenue Next 5Y4.23%
EBIT growth 1Y-20.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-1.68%
EBIT Next 3Y1.08%
EBIT Next 5Y5.95%
FCF growth 1Y9.39%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y21.97%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -11.58% in the next year.